As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

O Seu Dinheiro mostra para você como investir com inteligência, entregando notícias e análises sobre finanças, economia, ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

Resultados preliminares dos testes com a amicretina injetável foram anunciados pela Novo Nordisk nesta sexta-feira ...

The company released its results after market hours. The stock was down 0.71 per cent to Rs 3,243 per share on the BSE ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial. Shares were 9.5% higher ...

Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK515.00.

India's Torrent Pharmaceuticals reported a smaller-than-expected third-quarter profit on Friday, hurt by the planned closure of its insulin manufacturing facility.

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...